增强子重塑驱动白血病干细胞中MLL癌基因依赖的转录失调
该研究描绘了MLL基因重排急性髓系白血病(MLLr AML)中白血病干细胞(LSC)的活跃增强子景观,发现LSC存在广泛的增强子功能异常。研究重建调控网络并确定EP300是维持LSC致癌潜能的关键转录辅调节因子,其抑制剂A-485通过抑制组蛋白乙酰转移酶域靶向增强子活性影响LSC生长。
要点
- MLLr AML的LSC存在广泛的增强子功能异常和独特的活跃增强子景观。
- EP300通过调节H3K27乙酰化控制必需基因表达,是维持LSC致癌潜能的关键辅调节因子。
- EP300抑制剂A-485通过抑制组蛋白乙酰转移酶域靶向增强子活性,影响LSC生长。
核心结论
- MLLr特异性增强子可及性景观发生紊乱,提示破坏LSC增强子调控轴可能是AML有前景的治疗策略。
研究设计与样本
- 研究描绘了MLLr AML中LSC的活跃增强子景观,并重建了调控网络。
主要发现
- LSC存在广泛的增强子功能异常,调控网络重建揭示了一组核心造血转录因子。
- EP300通过调节H3K27乙酰化控制必需基因表达,是维持LSC致癌潜能的关键转录辅调节因子。
- EP300抑制剂A-485通过抑制组蛋白乙酰转移酶域靶向增强子活性,影响LSC生长。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acute myeloid leukemia (AML) with mixed-lineage leukemia (MLL) gene rearrangement (MLLr) comprises a cellular hierarchy in which a subpopulation of cells serves as functional leukemia stem cells (LSCs). They are maintained by a unique gene expression program and chromatin states, which are thought to reflect the actions of enhancers. Here, we delineate the active enhancer landscape and observe pervasive enhancer malfunction in LSCs. Reconstruction of regulatory networks revealed a master set of hematopoietic transcription factors. We show that EP300 is an essential transcriptional coregulator for maintaining LSC oncogenic potential because it controls essential gene expression through modulation of H3K27 acetylation and assessments of transcription factor dependencies. Moreover, the EP300 inhibitor A-485 affects LSC growth by targeting enhancer activity via histone acetyltransferase domain inhibition. Together, these data implicate a perturbed MLLr-specific enhancer accessibility landscape, suggesting the possibility for disruption of the LSC enhancer regulatory axis as a promising therapeutic strategy in AML.
引用
- Pan F, Iwasaki M, Wu W, et al. Enhancer remodeling drives MLL oncogene-dependent transcriptional dysregulation in leukemia stem cells. Blood Adv. 2023. PMID: 36705973. doi:10.1182/bloodadvances.2022008787
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。